You are hereDecember 21, 2017
What’s the Stem Cells Buzz this Week? - Cancer Immunotherapy, Cellular Conspiracy of ALS, Vav1-null HSPCs, and Leukemic BM Niche Adaptation!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
hPSCs in Cell-based Cancer Immunotherapy
The first of this week’s Reviews comes from the laboratory of Dan S. Kaufman (University of California San Diego, USA), who highlight the potential for human pluripotent stem cells (hPSCs) to produce immune cells that can target and treat refractory cancer subtypes. Zhu et al. describe how hPSC-derived cytotoxic T cells and natural killer (NK) cells can be engineered to foster anti-tumor activity and can be manufactured in huge numbers. See STEM CELLS now for what promises to be a fascinating read.
The Cellular Conspiracy of ALS
Research efforts towards an understanding of amyotrophic lateral sclerosis (ALS) concentrate, perhaps understandably, on the neurons lost during the development of the disease. However, a new review article from the labs of Andrea Serio (Kings College London) and Rickie Patani (University College London/The Francis Crick Institute, UK) suggests there may be another “cellular conspiracy” at play. See STEM CELLS now for all the information on how non-neural cells may be major determinants of ALS and how the integration of cross‐modal approaches may provide new therapeutic strategies.
IL‐11 inhibits engraftment of Vav1-null HSPCs
This week’s lone research article comes from researchers from the lab of David A. Williams (Harvard University, Boston, USA) who report on how deletion of Vav1, a hematopoietic-specific activator of Rac, compromises engraftment of transplanted adult HSPCs (hematopoietic stem and progenitor cells). Their new study indicates a requirement for Vav1 in the response of HSPCs to the irradiation-induced upregulation of the proinflammatory cytokine interleukin-11 (IL-11) in the bone marrow. See STEM CELLS for all the details.
Leukemic adaptation of the BM niche
This week’s last review, from the lab of Peter Kurre (Oregon Health & Science University, Portland, USA), discusses the bone marrow microenvironment as a critical contributor to therapeutic resistance and relapse progression in hematological malignancies. Doron et al. take this opportunity to discuss stromal conversion by leukemia and the resulting aberrant signaling within the niche, the advantages and limitations of available experimental model systems, and highlight current questions and any important opportunities. See STEM CELLS now for a great read!
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!